On October 29, 2019 Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported that it will host a Research and Development (R&D) Day for analysts and investors on Tuesday, November 5, 2019 beginning at 8:30 a.m. ET in New York City (Press release, Blueprint Medicines, OCT 29, 2019, View Source [SID1234549987]). In addition, the company will report its third quarter 2019 financial results on Tuesday, November 5, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day will feature presentations by Blueprint Medicines’ management team, which will review the company’s precision therapy research vision and portfolio, as well as a presentation from Dr. Cem Akin, M.D., Ph.D., Professor of Medicine, University of Michigan, who is an expert in the field of allergy and immunology, and whose work focuses on the treatment of mastocytosis.

A live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 90 days following the event.